
sRNAlytics: Pioneering small RNA research with technology and services for accelerated drug discovery.
sRNAlytics, founded with a mission to decode the RNA code driving diseases, focuses on pioneering small RNA research. Their core vision is to develop effective therapeutics by leveraging their AI-driven Code-Breakerâ„¢ platform, which decodes the landscape of small RNAs (sRNAs) to design biomarker-guided precision oligonucleotide therapeutics. The company offers technology and services aimed at accelerating drug discovery programs, with a market focus on developing therapies for pulmonary, cardiac, neurological, and autoimmune diseases.
Notable affiliated individuals include experts in biotechnology and artificial intelligence, though specific names are not provided. sRNAlytics has achieved significant milestones in advancing small RNA research and drug discovery, positioning itself as a leader in the field. Their innovative approach has garnered attention from key investors in the biotech sector. The impact of sRNAlytics is evident in their potential to transform therapeutic development and address complex diseases through precision medicine.

Gatehouse Bio
gatehousebio.com

Atomic AI
atomic.ai

Alltrna
alltrna.com

DeepCure
deepcure.ai

Nymirum

Envisagenics
envisagenics.com

NeuroX1
neurox1.com

Cognaisent
cognaisent.com

Scribe Biosciences

1910
1910genetics.com

Wayfinder Biosciences
wayfinderbio.com

Neurosnap
neurosnap.ai

Ribometrix
ribometrix.com

Nextrna Therapeutics

858 Therapeutics
8five8tx.com
Companies similar to Srnalytics include Gatehouse Bio, Atomic AI, Alltrna and DeepCure.
Srnalytics was founded in 2016.
Srnalytics' headquarters is located in Waltham, MA, US.
As of Mar 6, 2020, Srnalytics has raised a total of $2.5M (USD).
Srnalytics has 9 employees as of Feb 4, 2024.